Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022 | Press Releases

CUPERTINO, Calif., Sept. 07, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Sep 6, 2022 | Press Releases

CUPERTINO, Calif., Sept. 06, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Aug 15, 2022 | Press Releases

– Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial – – Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 – – $19.4 Million in Cash as of June 30, 2022 – CUPERTINO, Calif., Aug. 15,...

Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

Jul 27, 2022 | Press Releases

Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022 More than 20% of the approximately 400 patients planned for Phase 3...

Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

Jun 2, 2022 | Press Releases

CUPERTINO, Calif.,, June 02, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...